Mutations in the cyclophilin A (CypA) binding region in the HIV-1 capsid affect their dependency on the known HIV-1 cofactor CypA and allow escape from the HIV-1 restriction factor Trim5α in human and simian cells. Here we study the effect of these mutations in the CypA binding region of capsid on cofactor binding, capsid destabilization, and viral replication in primary cells. We showed that the viral capsid with mutations in the CypA binding region (CypA-BR) interacted efficiently with CypA, but had an increased stability upon infection as compared to the wild-type capsid. Interestingly, the wild-type virus was able to infect monocyte-derived macrophages (MDM) more efficiently as compared to the CypA-BR mutant variant. The lower infectivity of the CypA-BR mutant virus in MDM was associated with lower levels of reverse transcription products. Similar to the wild-type virus, the CypA-BR mutant variant was unable to induce a strong innate response in primary macrophages. These data demonstrate that mutations in the CypA binding site of the capsid resulted in higher capsid stability and hampered infectivity in macrophages.
Get full access to this article
View all access options for this article.
References
1.
BukovskyAA, WeimannA, AccolaMA, and GottlingerHG: Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc Natl Acad Sci USA, 1997; 94(20):10943–10948.
2.
GambleTR, VajdosFF, YooS, et al.: Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell, 1996; 87(7):1285–1294.
3.
FrankeEK, YuanHEH, and LubanJ: Specific incorporation of cyclophilin A into HIV-1 virions. Nature, 1994; 372:359–362.
4.
BraatenD, FrankeEK, and LubanJ: Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol, 1996; 70(6):3551–3560.
5.
TowersGJ, HatziioannouT, CowanS, et al.: Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med, 2003; 9(9):1138–1143.
6.
KootstraNA, MunkC, TonnuN, et al.: Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci USA, 2003; 100(3):1298–1303.
7.
HatziioannouT, Perez-CaballeroD, CowanS, and BieniaszPD: Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol, 2005; 79(1):176–183.
8.
SokolskajaE, SayahDM, and LubanJ: Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol, 2004; 78(23):12800–12808.
9.
FrankeEK and LubanJ: Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology, 1996; 222(1):279–282.
10.
BerthouxL, SebastianS, SokolskajaE, and LubanJ: Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci USA, 2005; 102(41):14849–14853.
11.
KeckesovaZ, YlinenLM, and TowersGJ: Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol, 2006; 80(10):4683–4690.
12.
StremlauM, SongB, JavanbakhtH, et al.: Cyclophilin A: An auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology, 2006; 351(1):112–120.
13.
RitsMA, van DortKA, MunkC, et al.: Efficient transduction of simian cells by HIV-1-based lentiviral vectors that contain mutations in the capsid protein. Mol Ther, 2007; 15(5):930–937.
14.
ChatterjiU, BobardtMD, StanfieldR, et al.: Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J Biol Chem, 2005; 280(48):40293–40300.
15.
IkedaY, YlinenLM, Kahar-BadorM, and TowersGJ: Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol, 2004; 78(21):11816–11822.
16.
KootstraNA, NavisM, BeugelingC, et al.: The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. AIDS, 2007; 21(15):2015–2023.
17.
NavisM, SchellensI, van BaarleD, et al.: Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol, 2007; 179(5):3133–3143.
18.
DullT, ZuffereyR, KellyM, et al.: A third-generation lentivirus vector with a conditional packaging system. J Virol, 1998; 72(11):8463–8471.
19.
KootstraNA, MatsumuraR, and VermaIM: Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther, 2003; 7(5 Pt 1):623–631.
20.
TersmetteM, WinkelIN, GroeninkM, et al.: Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology, 1989; 171:149–155.
21.
KootstraNA and SchuitemakerH: Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of GAG and Vpr is comparable to wild type HIV-1 in primary macrophages. Virology, 1999; 253(2):170–180.
22.
GanserBK, LiS, KlishkoVY, et al.: Assembly and analysis of conical models for the HIV-1 core. Science, 1999; 283(5398):80–83.
23.
FollenziA, AillesLE, BakovicS, et al.: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet, 2000; 25(2):217–222.
24.
StremlauM, PerronM, LeeM, et al.: Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA, 2006; 103(14):5514–5519.
25.
ButlerSL, HansenMS, and BushmanFD: A quantitative assay for HIV DNA integration in vivo. Nat Med, 2001; 7(5):631–634.
26.
FolksTM, PowellD, LightfooteMM, et al.: Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med, 1986; 164:280–290.
27.
YanN, Regalado-MagdosAD, StiggelboutB, et al.: The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol, 2010; 11(11):1005–1013.
28.
ChatterjiU, BobardtMD, GaskillP, et al.: Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem, 2006; 281(48):37025–37033.
29.
HulmeAE, KelleyZ, OkochaEA, and HopeTJ: Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells. J Virol, 2015; 89(1):643–651.
30.
RasaiyaahJ, TanCP, FletcherAJ, et al.: HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature, 2013; 503(7476):402–405.
31.
AmbroseZ, LeeK, NdjomouJ, et al.: Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol, 2012; 86(8):4708–4714.
32.
YinL, BraatenD, and LubanJ: Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol, 1998; 72(8):6430–6436.
33.
SongC and AikenC: Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant. J Virol, 2007; 81(21):11946–11956.
34.
QiM, YangR, and AikenC: Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells. J Virol, 2008; 82(24):12001–12008.
35.
YlinenLM, SchallerT, PriceA, et al.: Cyclophilin A levels dictate infection efficiency of human immunodeficiency virus type 1 capsid escape mutants A92E and G94D. J Virol, 2009; 83(4):2044–2047.
36.
MiuraT, BrockmanMA, SchneidewindA, et al.: HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol, 2009; 83(6):2743–2755.
37.
BrockmanMA, SchneidewindA, LahaieM, et al.: Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol, 2007; 81(22):12608–12618.
38.
GijsbersEF, FeenstraKA, van NuenenAC, et al.: HIV-1 replication fitness of HLA-B*57/58:01 CTL escape variants is restored by the accumulation of compensatory mutations in Gag. PLoS One, 2013; 8(12):e81235.
39.
BattivelliE, MigraineJ, LecossierD, et al.: Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5 alpha, linking intrinsic and acquired immunity. J Virol, 2011; 85(22):11846–11854.
40.
BattivelliE, LecossierD, MatsuokaS, et al.: Strain-specific differences in the impact of human TRIM5 alpha, different TRIM5 alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol, 2010; 84(21):11010–11019.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
